28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study aimed to determine the effectiveness of regular dental scaling by evaluating the association between the frequency of dental scaling and the risk of dementia in individuals with moderate to severe periodontal disease. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The model outperformed conventional ones, with an out-of-bag R2 of 74.8%. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty thousand three hundred and ninety-eight deaths attributable to dementia as the underlying or related cause (multiple causes) were reported during 2015-2019. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Understanding and addressing SDOH associated with hospitalizations among AI/AN older adults, with and without dementia, may aid in the development of strategies that reduce preventable hospitalization. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants exhibited strong awareness of the risks associated with complications and the severity of chronic diseases. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The overall NH admission rate among HCBS users with ADRD was 67%, 55%, and 36% for whites, blacks, and others, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obstructive sleep apnea (OSA), a prevalent sleep-disordered breathing condition, is increasingly recognized as a modifiable risk factor for cognitive decline and dementia, including Alzheimer’s disease and vascular dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Individuals aged 70 and above experiencing memory loss in Cochran and Parmer Counties had a statistically significant association with cognitive impairment (p < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Social isolation (SI) and loneliness (perceived social isolation) are considered as risk factors for developing dementia, including Alzheimer's disease (AD), in the elderly population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Researchers are focusing on modifiable risk factors for dementia, including sleep disturbances such as insomnia and sleep-disordered breathing (SDB), which are known to increase the risk of dementia, including Alzheimer’s disease (AD) and vascular dementia (VD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Acute ischemic stroke often results in a multitude of neuropsychiatric complications, including depression, dementia, delirium, and fatigue. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of dementia in older people in Seoul appears to be somewhat lower than in rural areas of Korea. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor compa 4 key findings →
Design: cohort study Participants: 14,364 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia and hearing loss are both highly prevalent conditions among older adults. 4 key findings →
Design: cohort study Participants: 25 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It is estimated that for people aged 65 years and older, the risk of developing Alzheimer’s disease was nearly double for women compared with men (Weinstein et al., 2012). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitively normal older adults are often regarded as a homogeneous population in preventive and disease-modifying clinical trials for dementia. 2 key findings →
Design: prospective cohort Participants: 1,136 Evidence: moderate
Full summary, score breakdown and related studies → Original source
AbstractO_ST_ABSBackgroundC_ST_ABSGlucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. 5 key findings →
Participants: 6,328 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We examined whether their metabolomic profiles also differed and whether subtype-related metabolic patterns were associated with dementia, stroke, and all-cause mortality. 5 key findings →
Participants: 7,671 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Persistent racial disparities in dementia raise concerns regarding the validity and generalizability of existing prognostic models across diverse populations. 2 key findings →
Participants: 55,004 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BACKGROUNDPeople with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. 5 key findings →
Design: cohort study Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source
BackgroundPhenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes. 4 key findings →
Design: longitudinal study Participants: 272 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundFear of dementia (FoD) can shape psychological well-being and responses to perceived cognitive change. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
It remains unclear whether the combined conditions confer an excess risk of hypoglycaemia-related hospitalisation beyond the risks associated with either condition alone. 5 key findings →
Design: longitudinal study Participants: 329,566 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 13 years, 5,304 participants developed dementia. 4 key findings →
Participants: 151,832 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is a potential risk factor for dementia, but public awareness of this link and its behavioral implications remain poorly understood. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
8 of the 1,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →